Bipartisan Majority Backs Prescription Drug, Credit Card and Child‑Care Price Caps, WSJ Poll Shows
A Wall Street Journal poll released in early October 2026 found bipartisan majorities supporting government limits on prescription drug prices, credit‑card interest rates and child‑care costs.
The poll showed 93% of Democrats and 83% of Republicans favor capping the price of prescription medicines, and roughly 80% of all voters backed a 10% ceiling on credit‑card interest rates. Large majorities also supported limits on the cost of child‑care for working families. The findings highlight a broad‑based populist appetite for price‑control policies across health, finance and family‑support sectors.
Political leaders from both parties have echoed the sentiment. Democratic socialist Senator Bernie Sanders and Republican Senator Josh Hawley both endorse a 10% credit‑card rate cap. Democratic Senator Elizabeth Warren has championed child‑care cost limits, while former President Donald Trump promoted a government website offering discounted prescription drugs. The cross‑party alignment illustrates how price‑control proposals have become a unifying theme in the current political climate.
Economists, however, caution that the appeal of price caps often overlooks hidden costs. As former President Ronald Reagan famously warned, “the nine most terrifying words in the English language are: I’m from the government, and I’m here to help.” Government‑imposed ceilings can distort market signals that balance supply and demand, leading to unintended consequences such as empty shelves or reduced service availability.
In the credit‑card market, a 10% interest‑rate ceiling would force lenders to price credit below their funding costs and risk premiums. When the capped price falls short of the risk‑adjusted cost of lending, banks may tighten credit, reduce limits or close accounts, pushing consumers toward higher‑cost alternatives like payday lenders or pawn shops. The policy intended to protect vulnerable borrowers could instead restrict their access to affordable credit.
Child‑care providers face a similar dilemma. High labor costs and regulatory requirements already constrain supply. Capping prices without addressing the underlying cost structure could force providers to cut staff, reduce hours or shut down altogether, leaving families with fewer available slots despite lower advertised rates.
The pharmaceutical sector presents a more complex trade‑off. While lower drug prices can provide immediate relief to patients, price caps may erode the revenue streams that fund research and development. The high risk and expense of bringing new medicines to market rely on future earnings expectations; reducing those expectations could slow the pipeline of innovative treatments, ultimately affecting public health.
Policymakers are now weighing the political momentum behind price‑control proposals against the economic analyses warning of supply‑side repercussions. As lawmakers consider legislation in the coming months, the debate will likely center on whether short‑term consumer relief justifies potential long‑term costs to credit access, child‑care availability and drug innovation.
